Journal of Allergy & Therapy

Jörg Schnitker

Publications

• Research Article
  Intra-Seasonal Short-Time Up-Dosing with SQ-Standardised Subcutaneous Immunotherapy in Patients with Intermittent Allergic Rhinoconjunctivitis is Well Tolerated during Routine Application: A Non-Interventional, Observational Study
  Author(s): Rainer Reiber, Hendrik Wolf, Jörg Schnitker and Eike WüstenbergRainer Reiber, Hendrik Wolf, Jörg Schnitker and Eike Wüstenberg
  
  Background: For patients with pollen induced allergic rhinoconjunctivitis, a pre-seasonal start of subcutaneous specific immunotherapy is generally recommended in international guidelines. In a placebo-controlled trial intraseasonal up-dosing of subcutaneous immunotherapy to 10,000 SQ-U (Alutard SQ®) was shown to be well tolerated and to induce significant immunologic effects. The aim of our study was to investigate the feasibility of intra-seasonal up-dosing during routine application. Methods: In an open, non-interventional observational study, data on tolerability of subcutaneous immunotherapy (Alutard SQ®) in patients with grass pollen induced allergic rhinoconjunctivitis were recorded by 110 physicians between May and November 2009 in Germany. Therapy was initiated within grass pollen season according to a 6-injection up-dosing schedule from 100 to 10,000 SQ-U wit.. View More»
  DOI: 10.4172/2155-6121.1000137

  Abstract PDF